FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine.
暂无分享,去创建一个
Hubert Vesselle | H. Vesselle | J. Grierson | Alexander Salskov | Varaha S Tammisetti | John Grierson | V. Tammisetti | Alexander Salskov
[1] Kyung-Ja Cho,et al. Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[2] T K Lewellen,et al. Carbon-11-thymidine and FDG to measure therapy response. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] M. Muzi,et al. Metabolism of 3'-deoxy-3'-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. , 2004, Nuclear medicine and biology.
[4] H. Hoekstra,et al. 3'-18F-fluoro-3'-deoxy-L-thymidine: a new tracer for staging metastatic melanoma? , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] Y. Yonekura,et al. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. , 2002, Nuclear medicine and biology.
[6] W. Mikulits,et al. Overexpression of Thymidine Kinase mRNA Eliminates Cell Cycle Regulation of Thymidine Kinase Enzyme Activity (*) , 1996, The Journal of Biological Chemistry.
[7] H. Sakahara,et al. Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] Mark Muzi,et al. True tracers: comparing FDG with glucose and FLT with thymidine. , 2005, Nuclear medicine and biology.
[9] H. Dittmann,et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[10] H. Vesselle,et al. Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-[18F]fluorothymidine (18F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses , 2007, BMC nuclear medicine.
[11] J. Baak,et al. Prognostic value of proliferation in invasive breast cancer: a review , 2004, Journal of Clinical Pathology.
[12] Karl Herholz,et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] I. McNeish,et al. Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging. , 2006, Cancer research.
[14] Y. Nishiyama,et al. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[15] L. Ståhle,et al. Transport of alovudine (3'-fluorothymidine) into the brain and the cerebrospinal fluid of the rat, studied by microdialysis. , 2000, Life sciences.
[16] J. Lafitte,et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.
[17] S. Conrad,et al. Independent regulation of thymidine kinase mRNA and enzyme levels in serum-stimulated cells. , 1990, The Journal of biological chemistry.
[18] M. Berger,et al. 2-[C-11]thymidine imaging of malignant brain tumors. , 1999, Cancer research.
[19] D. Wood,et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] Otto Muzik,et al. A simplified analysis of [18F]3′-deoxy-3′-fluorothymidine metabolism and retention , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[21] W. Vaalburg,et al. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] C. Dence,et al. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] Falko Fend,et al. Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma , 2007, Clinical Cancer Research.
[24] Ur Metser,et al. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. , 2007, Seminars in nuclear medicine.
[25] W. Vaalburg,et al. Detection and Grading of Soft Tissue Sarcomas of the Extremities with 18F-3′-Fluoro-3′-Deoxy-l-Thymidine , 2004, Clinical Cancer Research.
[26] J. Sherley,et al. Regulation of human thymidine kinase during the cell cycle. , 1988, The Journal of biological chemistry.
[27] K. Krohn,et al. Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3'-deoxy-3'fluorothymidine uptake. , 2004, Nuclear medicine and biology.
[28] Jae Seung Kim,et al. [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[29] K. Ishiwata,et al. Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] C S Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[31] U. Haberkorn,et al. Synthesis of 3′‐deoxy‐3′‐[18F]fluoro‐thymidine with 2,3′‐anhydro‐5′‐O‐(4,4′‐dimethoxytrityl)‐thymidine , 2000 .
[32] J. R. Grierson,et al. Simplified Labeling Approach for Synthesizing 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT) , 2000 .
[33] S. Eriksson,et al. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. , 1991, The Journal of biological chemistry.
[34] J B Bassingthwaighte,et al. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] T. Chou,et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine , 1992, Antimicrobial Agents and Chemotherapy.
[36] T. Mattfeldt,et al. Molecular imaging of proliferation in malignant lymphoma. , 2006, Cancer research.
[37] M. Hirsch,et al. Enhanced in vitro inhibition of HIV-1 replication by 3'-fluoro-3'-deoxythymidine compared to several other nucleoside analogs. , 1988, AIDS Research and Human Retroviruses.
[38] H. Dittmann,et al. [18F]FLT PET for diagnosis and staging of thoracic tumours , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[39] Otto Muzik,et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.
[40] A. Harris,et al. Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. , 2004, Biochimica et biophysica acta.
[41] D. Mankoff,et al. A graphical analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[42] E. Wintersberger,et al. Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. , 1994, The Journal of biological chemistry.
[43] D. Visvikis,et al. Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[44] D. Mankoff,et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[45] Michael E Phelps,et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. , 2006, Chest.
[46] Qimin He,et al. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. , 2003, Cancer research.
[47] T. Powles,et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma , 2000, Cancer.
[48] K. Gatter,et al. Ki67 protein: the immaculate deception? , 2002, Histopathology.
[49] F. O’Sullivan,et al. Kinetic Analysis of 2-[11C]Thymidine PET Imaging Studies of Malignant Brain Tumors: Compartmental Model Investigation and Mathematical Analysis , 2002 .
[50] Gerald Reischl,et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[51] L. Wiens,et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[52] S. Reske,et al. [18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot study. , 2004, Cancer biotherapy & radiopharmaceuticals.
[53] E. Wintersberger,et al. Regulation of thymidine kinase during growth, cell cycle and differentiation. , 1992, Advances in enzyme regulation.
[54] Eric O. Aboagye,et al. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[55] B. Drayer,et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? , 1998, AJNR. American journal of neuroradiology.
[56] Torsten Mattfeldt,et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[57] K. Krohn,et al. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[58] C. Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[59] Stephen R Thomas,et al. MIRD dose estimate report no. 19: radiation absorbed dose estimates from (18)F-FDG. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[60] M. Kitajima,et al. Cell-Cycle Regulators and the Ki-67 Labeling Index Can Predict the Response to Chemoradiotherapy and the Survival of Patients With Locally Advanced Squamous Cell Carcinoma of the Esophagus , 2003, Annals of Surgical Oncology.
[61] H. Hoekstra,et al. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[62] Janet F. Eary,et al. Kinetic Analysis of 2-[11C]Thymidine PET Imaging Studies of Malignant Brain Tumors: Preliminary Patient Results , 2002 .
[63] J. Wesseling,et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[64] C Flexner,et al. Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. , 1994, The Journal of infectious diseases.
[65] J Grierson,et al. Utilization of labeled thymidine in DNA synthesis: studies for PET. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[66] Mark Muzi,et al. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[67] B. Oberg,et al. Penetration of zidovudine and 3'-fluoro-3'-deoxythymidine into the brain, muscle tissue, and veins in cynomolgus monkeys: relation to antiviral action , 1992, Antimicrobial Agents and Chemotherapy.
[68] Mark Muzi,et al. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[69] D. Mankoff,et al. Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[70] H. Vesselle,et al. FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. , 1998, Radiographics : a review publication of the Radiological Society of North America, Inc.
[71] S. Osman,et al. Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies. , 2002, Cancer research.
[72] A. Shields,et al. Radiosynthesis of 3'-deoxy-3'-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. , 2000, Nuclear medicine and biology.
[73] P. Martiat,et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[74] F. O’Sullivan,et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results. , 2002, Molecular imaging.
[75] Paul Workman,et al. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. , 2006, Cancer research.
[76] Michael E. Phelps,et al. Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy , 2005, Molecular Imaging and Biology.
[77] T. Mattfeldt,et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[78] T. Mattfeldt,et al. Clinical relevance of imaging proliferative activity in lung nodules , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[79] Bengt Långström,et al. Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[80] Ludwig G. Strauss,et al. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients , 1996, European Journal of Nuclear Medicine.
[81] Adeeba Kamarulzaman,et al. AIDS Res Hum Retroviruses , 2006 .
[82] J. Ajani,et al. Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor Models , 2006, Clinical Cancer Research.
[83] Mark Muzi,et al. Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[84] H. Groen,et al. Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[85] Y. Yonekura,et al. Acquisition of resistance to antitumor alkylating agent ACNU: a possible target of positron emission tomography monitoring. , 2006, Nuclear medicine and biology.
[86] H. Hoekstra,et al. Positron emission tomography in patients with breast cancer using (18)F-3'-deoxy-3'-fluoro-l-thymidine ((18)F-FLT)-a pilot study. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[87] Sven N Reske,et al. 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. , 2003, Cancer research.
[88] D. Kinzel,et al. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[89] S. Shousha,et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. , 2005, Cancer research.
[90] P. Price,et al. The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[91] W. Oyen,et al. 18F-FLT PET Does Not Discriminate Between Reactive and Metastatic Lymph Nodes in Primary Head and Neck Cancer Patients , 2007, Journal of Nuclear Medicine.
[92] D. Mankoff,et al. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[93] T. Manabe,et al. Evaluation of Primary Brain Tumors With FLT-PET: Usefulness and Limitations , 2006, Clinical nuclear medicine.
[94] Mark Muzi,et al. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[95] Mark Muzi,et al. Positron emission tomography imaging of brain tumors. , 2003, Neuroimaging clinics of North America.
[96] H. Vesselle,et al. The Ki‐67 Index and Survival in Non‐‐‐Small Cell Lung Cancer: A Review and Relevance to Positron Emission Tomography , 2002, Cancer journal.
[97] M. J. van de Vijver,et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome , 2003, British Journal of Cancer.
[98] H. Vesselle,et al. A SepPak unit for batch processing serial blood plasma samples for PET , 2007 .
[99] E. Aboagye,et al. Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. , 2005, Cancer research.
[100] D. Mankoff,et al. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[101] Marvin Bergsneider,et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.